Conversely, dual pharmacologic targeting of TGF-β and AURKA pathways efficiently reverses chemoresistance and impairs tumor progression through SNAI1 down-regulation, inhibition of cancer cell plasticity, and selective targeting of ALDH1high cells (Fig. 8d). The gene discussed is SNAI1; the disease is neoplasm.